These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 25111859)

  • 1. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
    Fiteni F; Nguyen T; Vernerey D; Paillard MJ; Kim S; Demarchi M; Fein F; Borg C; Bonnetain F; Pivot X
    Cancer Med; 2014 Dec; 3(6):1502-11. PubMed ID: 25111859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
    Lee J; Park SH; Chang HM; Kim JS; Choi HJ; Lee MA; Jang JS; Jeung HC; Kang JH; Lee HW; Shin DB; Kang HJ; Sun JM; Park JO; Park YS; Kang WK; Lim HY
    Lancet Oncol; 2012 Feb; 13(2):181-8. PubMed ID: 22192731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
    Yang R; Wang B; Chen YJ; Li HB; Hu JB; Zou SQ
    Anticancer Drugs; 2013 Sep; 24(8):871-7. PubMed ID: 23799294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
    Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
    Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
    Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
    Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.
    Hollebecque A; Bouché O; Romano O; Scaglia E; Cattan S; Zerbib P; Heurgue A; Lagarde S; Mariette C; Triboulet JP; Pruvot FR; Hebbar M
    Chemotherapy; 2010; 56(3):234-8. PubMed ID: 20551640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
    Manzione L; Romano R; Germano D
    Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
    Valle JW; Wasan H; Lopes A; Backen AC; Palmer DH; Morris K; Duggan M; Cunningham D; Anthoney DA; Corrie P; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; Beare S; Dive C; Bridgewater JA
    Lancet Oncol; 2015 Aug; 16(8):967-78. PubMed ID: 26179201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas.
    Halim A; Ebrahim MA; Saleh Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):217-24. PubMed ID: 21062755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
    Hezel AF; Noel MS; Allen JN; Abrams TA; Yurgelun M; Faris JE; Goyal L; Clark JW; Blaszkowsky LS; Murphy JE; Zheng H; Khorana AA; Connolly GC; Hyrien O; Baran A; Herr M; Ng K; Sheehan S; Harris DJ; Regan E; Borger DR; Iafrate AJ; Fuchs C; Ryan DP; Zhu AX
    Br J Cancer; 2014 Jul; 111(3):430-6. PubMed ID: 24960403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
    Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
    Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
    Novarino AM; Satolli MA; Chiappino I; Giacobino A; Napoletano R; Ceccarelli M; Ciccone G; Schena M; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2013 Oct; 36(5):466-71. PubMed ID: 22781390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
    Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
    Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.
    Harder J; Riecken B; Kummer O; Lohrmann C; Otto F; Usadel H; Geissler M; Opitz O; Henss H
    Br J Cancer; 2006 Oct; 95(7):848-52. PubMed ID: 16969352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
    Fornaro L; Vivaldi C; Cereda S; Leone F; Aprile G; Lonardi S; Silvestris N; Santini D; Milella M; Caparello C; Musettini G; Pasquini G; Falcone A; Brandi G; Sperduti I; Vasile E;
    J Exp Clin Cancer Res; 2015 Dec; 34():156. PubMed ID: 26693938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
    Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.